Compare Organon & Co. Common Stock (OGN) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs TORM plc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while TORM plc trades at $39.22 (market cap $4.21B). The key difference: TORM plc is the larger of the two by market cap, and TORM plc pays the higher dividend (10.75%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and TORM plc for 23 Days on average.
| OGN | TRMD | |
|---|---|---|
Market Cap | $3.62B | $4.21B |
Volume | 2,892,999 | 1,504,714 |
Sector | Health | Industrials |
52-Week High | $13.81 | $41.11 |
52-Week Low | $5.70 | $19.39 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.04B | $4.92B |
Dividend Yield | 0.58% | 10.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TRMD trades at $41.11, up 0.46% with strong bullish technical signals from moving averages. The company shows robust fundamentals with a P/E of 6.76, net income margin of 35.52%, and ROE of 26.84%. Recent earnings show mixed results with Q2 2026 missing expectations but strong year-over-year growth projected. Analyst consensus is unanimously bullish with 100% buy ratings. The stock faces headwinds from declining spot rates as noted in recent analysis.
Outlook remains positive based on strong profitability and valuation metrics, though near-term pressure from freight rate declines presents risk. The dividend yield of approximately 5.8% provides income support. Institutional accumulation and solid cash flow generation support the bullish case, but investors should monitor tanker rate trends closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
